Ascendia

  MARKET NEWS

InnoGI Technologies Launches TIM Cell to Bridge the Gap Between Bioaccessibility and Absorption
Aptar Active Material Science Secures USPTO Allowance for N-Sorb Technology, Establishing First-of-Its-Kind Packaging-Delivered Approach to Nitrosamine Risk Mitigation
Quantum BioPharma Ltd. Advances Proprietary Therapy for Multiple Sclerosis Treatment
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

  EXPERT CONTENT & RESOURCES

 

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

On-Demand Presentation: Analytical Strategy & Challenges for ADC

On-Demand Presentation: Analytical Strategy & Challenges for ADC

Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.

Portrait of Bryn L. Dubin

America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready

Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Better Bioavailability Faster Timelines with Ascendia Pharmaceutical Solutions

Better Bioavailability Faster Timelines with Ascendia Pharmaceutical Solutions

  COMPANY PROFILE

BASF Pharma Solutions is a leading provider of innovative and high-quality excipients and APIs for the pharmaceutical industry. Our dedicated team of industry experts, supported by our cutting-edge digital solutions, works closely with customers to develop efficient and reliable formulations.

Based in Florham Park, United States, our operations span across the globe, with production facilities that spread across multiple continents, we are able to provide support and solutions to pharmaceutical industries worldwide.

Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 24 – Excipients
July 1 – Prefilled Syringes
July 8 – Analytical Testing
July 15 – ODT/Fast Dissolve